A meta-analysis confirms that neoadjuvant chemoimmunotherapy improves survival outcomes in most patients with resectable NSCLC, except for overall survival in patients with baseline PD-L1 below 1%.
The percentage of Canadian women who have survived breast cancer has doubled in the past 15 years, according to researchers at the University of Toronto, a reflection of the dramatic advances in the treatment of the disease in recent years.